Last reviewed · How we verify
Sorafenib Standard Dosing Regimen
Sorafenib is a multi-kinase inhibitor that blocks several receptor tyrosine kinases involved in tumor cell proliferation and angiogenesis.
Sorafenib is a multi-kinase inhibitor that blocks several receptor tyrosine kinases involved in tumor cell proliferation and angiogenesis. Used for Advanced renal cell carcinoma, Unresectable hepatocellular carcinoma, Radioactive iodine-refractory differentiated thyroid cancer.
At a glance
| Generic name | Sorafenib Standard Dosing Regimen |
|---|---|
| Also known as | Nexavar(Bay43-9006) |
| Sponsor | University of Florida |
| Drug class | Multi-kinase inhibitor |
| Target | BRAF, VEGFR-2, VEGFR-3, PDGFR-β, FLT-3, c-KIT |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Sorafenib inhibits multiple targets including BRAF, VEGFR-2, VEGFR-3, PDGFR-β, FLT-3, and c-KIT. By blocking these kinases, it suppresses both tumor cell growth directly and the formation of new blood vessels that feed tumors (angiogenesis), thereby limiting tumor progression.
Approved indications
- Advanced renal cell carcinoma
- Unresectable hepatocellular carcinoma
- Radioactive iodine-refractory differentiated thyroid cancer
Common side effects
- Hand-foot skin reaction
- Diarrhea
- Rash
- Fatigue
- Hypertension
- Nausea
- Alopecia
- Bleeding
Key clinical trials
- Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC) (PHASE2)
- Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sorafenib Standard Dosing Regimen CI brief — competitive landscape report
- Sorafenib Standard Dosing Regimen updates RSS · CI watch RSS
- University of Florida portfolio CI